PMEL and melanoma: In a phase III trial, including 676 patients with pretreated metastatic, unresectable stage III or IV melanoma, ipilimumab, alone or in combination with glycoprotein 100 peptide vaccine (gp100), demonstrated enhanced overall survival compared to gp100 alone.